ArcticZymes Technologies Valuation
Is 0DRV undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0DRV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0DRV (NOK13.24) is trading below our estimate of fair value (NOK37.02)
Significantly Below Fair Value: 0DRV is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0DRV?
Key metric: As 0DRV is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 0DRV's PE Ratio? | |
|---|---|
| PE Ratio | 146.8x |
| Earnings | NOK 4.63m |
| Market Cap | NOK 679.25m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4x |
| Enterprise Value/EBITDA | 594x |
| PEG Ratio | 1.8x |
Price to Earnings Ratio vs Peers
How does 0DRV's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 60.5x | ||
BVXP Bioventix | 24.2x | n/a | UK£195.7m |
GNS Genus | 142.9x | 37.7% | UK£1.1b |
EAH ECO Animal Health Group | 42.7x | 34.2% | UK£44.7m |
ANCR Animalcare Group | 32.1x | 15.8% | UK£148.5m |
0DRV ArcticZymes Technologies | 146.8x | 80.1% | NOK 679.2m |
Price-To-Earnings vs Peers: 0DRV is expensive based on its Price-To-Earnings Ratio (146.8x) compared to the peer average (60.5x).
Price to Earnings Ratio vs Industry
How does 0DRV's PE Ratio compare vs other companies in the European Biotechs Industry?
| 5 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 0DRV is expensive based on its Price-To-Earnings Ratio (146.8x) compared to the European Biotechs industry average (27x).
Price to Earnings Ratio vs Fair Ratio
What is 0DRV's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 146.8x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 0DRV's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | NOK 13.24 | NOK 16.00 +20.8% | 6.3% | NOK 17.00 | NOK 15.00 | n/a | 2 |
| Oct ’25 | NOK 17.00 | NOK 24.50 +44.1% | 6.1% | NOK 26.00 | NOK 23.00 | n/a | 2 |
| Sep ’25 | NOK 18.98 | NOK 24.50 +29.1% | 6.1% | NOK 26.00 | NOK 23.00 | n/a | 2 |
| Aug ’25 | NOK 25.70 | NOK 27.50 +7.0% | 9.1% | NOK 30.00 | NOK 25.00 | n/a | 2 |
| Jul ’25 | NOK 25.85 | NOK 27.50 +6.4% | 9.1% | NOK 30.00 | NOK 25.00 | n/a | 2 |
| Jun ’25 | NOK 24.50 | NOK 27.50 +12.2% | 9.1% | NOK 30.00 | NOK 25.00 | n/a | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Laboratorios Farmaceuticos Rovi
€3.2b
Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.
0ILL
€62.90
7D
1.5%
1Y
14.6%
hVIVO
UK£149.7m
Operates as a pharmaceutical service and contract research company in the United Kingdom.
HVO
UK£0.22
7D
-16.2%
1Y
22.2%
Regeneron Pharmaceuticals
US$79.4b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
0R2M
US$748.39
7D
-1.7%
1Y
-6.3%